Journal
NEUROPHARMACOLOGY
Volume 136, Issue -, Pages 192-195Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuropharm.2017.09.016
Keywords
Alzheimer's disease; Insulin; Amyloid-beta; Tau; mTOR
Categories
Funding
- Owens Family Foundation
- NIH [RF1 AG051085]
- Cure Alzheimer's Fund
- Alzheimer's Association [4079, ZEN-16-363266]
- Virginia Chapter of the Lady's Auxiliary of the Fraternal Order of Eagles
- University of Virginia President's Fund for Excellence
- Alzheimer's and Related Diseases Research Award Fund [17-5]
Ask authors/readers for more resources
The synaptic dysfunction and death of neurons that mediate memory and cognition account together for the behavioral symptoms of Alzheimer's disease (AD). Reduced insulin signaling in the brain is a hallmark of AD patients, even in the absence of systemic type 1 or type 2 diabetes, prompting some researchers to refer to AD as brain-specific, or type 3 diabetes. A key question that arises about this signature feature of AD is how, if at all, does the brain's impaired ability to utilize insulin contribute to the behavioral deficits associated with AD? The fact that type 2 diabetes is a risk factor for AD suggests a causative role for impaired insulin responsiveness in AD pathogenesis, but how that might occur at a detailed molecular level had been elusive. Here we review recent findings that mechanistically link soluble forms of amyloid-beta (A beta) and tau, the respective building blocks of the amyloid plaques and neurofibrillary tangles that accumulate in the brains of AD patients, with neuronal decline that is associated with poor insulin responsiveness and may begin long before AD symptoms become evident. We discuss how A beta and tau work coordinately to deprive neurons of functionally accessible insulin receptors and dysregulate normal signaling by the protein kinase, mTOR. Finally, we suggest how newly gained knowledge about pathogenic signaling caused by reduced brain insulin signaling might be exploited for improved early detection and therapeutic intervention for AD. This article is part of the Special Issue entitled 'Metabolic Impairment as Risk Factors for Neurodegenerative Disorders.' (C) 2017 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available